Publications without Fulltext
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14288/3
Browse
33 results
Search Results
Item Metadata only A novel weight optimized dynamic conformal arcs with TrueBeam™ Linac for very small tumors (≤1 cc) with single isocenter of multiple brain metastases (2≤, ≥4) in stereotactic radiosurgery: a comparison with volumetric modulated arc therapy(Wolters Kluwer Medknow Publications, 2023) 0000-0003-1151-4616; N/A; Sağlam, Yücel; Doctor; School of MedicineIntroduction: We evaluated whether improved increase delivery efficiency of weight optimized dynamic conformal arc (WO-DCA) therapy in comparison to volumetric modulated arc therapy (VMAT) with single isocenter for SRS treatment of very small volume and multiple brain metastases (BMs). Materials and Methods: 20 patients having a less than 1 cc volume and 2 <=, >= 4 of multiple BMs, redesigned for 20 Gy in 1 fraction using WO-DCA and VMAT techniques with double full coplanar and three partial noncoplanar arcs. Plan qualities were compared using tumor coverage, conformity index (CI), gradient index (GI), V-4Gy, V-10Gy, and V-12Gy volumes of brain, monitor units (MUs), and percent of quality assurance pass rate (QA%). Results: Both techniques satisfied clinical requirements in coverage and CI. VMAT had a significantly higher MU and mean GI than WO-DCA (for MUs; 2330 vs. 1991; P < 0.001, and for GI; 4.72 vs. 3.39; P < 0.001). WO-DCA was found significantly lower V-4Gy (171.11 vs. 232.80 cm(3), P < 0.001), V-10Gy (25.82 vs. 29.71 cm(3), P < 0.05), and V-12Gy (14.35 vs. 17.28 cm(3), P < 0.05) volumes than VMAT. WO-DCA was associated with markedly increase QA pass rates for all plans (97.65% vs. 92.64%, P < 0.001). Conclusions: WO-DCA may be the first choice compared to the VMAT in reducing the dose in the brain and minimizing small-field dosimetric errors for very small SRS treatment of brain metastases in the range of <= 1 cc and 2 <=, >= 4.Item Metadata only Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences(Wolters Kluwer Medknow Publications, 2023) 0000-0001-5804-6800; Tas, Faruk; Ferhatoglu, Ferhat; N/A; Ertürk, Kayhan; Faculty Member; School of MedicineIntroduction: The incidence of cutaneous melanoma among the elderly has increased significantly. Unfavorable survival rates are associated with insufficient patient managements and poor prognostic features in the elderly. We aimed to compare elderly (≥75 years) and younger (<75 years) patients with cutaneous melanoma to determine the differences and the prognostic significance of age. Materials and Methods: The retrospective data of 117 elderly and 232 younger patients with cutaneous melanoma were compared. Results: The median age of the elderly patients was 78 years (75-104), and 51.3% of the patients were female. Of the patients, 14.5% were in the metastatic stages. Clinicopathologic factors such as extremity melanomas (P = 0.01), Clark levels IV-V (P = 0.04), ulceration (P = 0.009), and neurotropism (P = 0.03) were significantly more common in elderly patients. However, BRAF mutation was significantly more common in younger patients (P = 0.003). Overall survival (OS) and recurrence-free survival (RFS) rates of both the groups were similar. Lymph node involvement (P < 0.005), distant metastasis (P < 0.005), and relapse of disease (P = 0.02) were associated with poor OS in elderly patients. Tumor-infiltrating lymphocytes was associated with prolonged RFS (P = 0.05), while extremity melanomas (P = 0.01), lymphovascular invasion (P = 0.006), and lymph node involvement (P < 0.005) had negative impact on RFS. Conclusions: Although elderly patients with cutaneous melanoma had different clinicopathologic features in our series, their survival rates are similar to those of younger patients, which shows that age alone is inadequate to determine the prognosis. Disease stage and a comprehensive geriatric assessment might assist to determine appropriate management.Item Metadata only Turkey's contribution to cancer publication: expected quantity, unsatisfactory quality(Wolters Kluwer Medknow Publications, 2023) 0000-0001-5804-6800; Tas, Faruk; N/A; Ertürk, Kayhan; Faculty Member; School of MedicineItem Metadata only Does F-18 FDG-PET/CT have an additional impact on axillary approach in early-stage breast cancer?(Galenos Publishing House, 2023) 0000-0003-4822-9755; 0000-0003-0160-0350; N/A; Böge, Medine; Dilege, Ece; Çelik, Burak; Faculty Member; Faculty Member; Researcher; School of Medicine; School of Medicine; School of Medicine; 288293; 218050; N/AObjective: Breast cancer (BC) is a significant health concern and one of the most diagnosed cancers in women, both in Turkey and globally. Despite advances in the management of BC, axillary lymph node involvement remains a significant consideration for treatment planning, local recurrence, and prognosis. We aimed to evaluate the contribution of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography (F-18 FDG-PET/CT) in detecting axillary lymph node metastasis compared to ultrasound (US). Materials and Methods: Eighty patients who were diagnosed with stage I and II BC and underwent US and F-18 FDG-PET/CT scans before surgery were enrolled in this study. Those who did not undergo F-18 FDG-PET/CT imaging, patients with distant metastases at the time of diagnosis and patients with micrometastases in the axilla were excluded from the analysis. Imaging results of the status of axillary lymph nodes were verified with the final pathology report of axillary lymph nodes. Results: The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of F-18 FDG-PET/CT for the detection of ipsilateral axillary lymph node metastases were 75%, 77.27%, 72.97%, 79.07%, and 76.25%. The corresponding values for US were 72.22%, 81.82%, 76.47%, 78.26%, and 77.50%, respectively. When US finding is negative or suspicious in axillary lymph node evaluation, the accuracy of F-18 FDG-PET/CT for the detection of ipsilateral axillary lymph node metastases were 65.38%, 83.33%, 70.83%, and 79.55%, respectively. Conclusion: This study found that F-18 FDG-PET/CT does not provide an additional advantage over US in assessing the axilla in early-stage disease.Item Metadata only Celebrating oncology nursing: from adversity to opportunity. The Global Power of Oncology Nursing Conference held virtually on the 15th November 2022(Ecancer Global Foundation, 2023) 0000-0002-9585-6332; Downing, Julia; Burns, Kathryn; Challinor, Julia; Cruickshank, Susanne; de Villiers, Martje; de la Serna, Celia Diez de Los Rios; Doumit, Myrna; Kumaralingam, Nellie; Lodge, Mark; Mendoza, Lucia Robles; Rassam, Rima Saad; Samba, Vera; Tomlins, Elaine; Young, Annie; N/A; Bağçivan, Gülcan; Faculty Member; School of Nursing; 261422The Global Power of Oncology Nursing held their 3rd annual conference on 'Celebrating Oncology Nursing: From Adversity to Opportunity'. The conference, held virtually, addressed three major nursing challenges: health workforce and migration, climate change and cancer nursing within humanitarian settings. Around the world, nurses are working in situations of adversity, whether due to the ongoing pandemic, humanitarian crises such as war or floods, shortage of nurses and other health workers, and high clinical demands leading to overwork, stress and burnout. The conference was held in two parts in order to take into account different time zones. Three hundred and fifty participants attended from 46 countries, with part of the conference being held in both English and Spanish. It was an opportunity for oncology nurses around the world to share their expe-riences and the realities for their patients seeking care and their families. The conference took the form of panel discussions, videos, and individual presentations from all six WHO regions and highlighted the importance of oncology nurses role in expanding beyond caring for individuals and their families, to tackle wider issues, such as nurse migration, climate change and care within humanitarian settings.Item Metadata only Climate change in Türkiye and its impact on oncology nurses(Ecancer Global Foundation, 2023) 0000-0002-9585-6332; Kaya, Afsin Ahmet; Aydin, Aydanur; N/A; Bağçivan, Gülcan; Faculty Member; School of Nursing; 261422Climate change threatens human life and health by negatively affecting the basic components of health such as clean air, safe drinking water, nutritious food supply, and safe shelter. Turkiye is a country that is largely exposed to climate change with its cosmopolitan location, which is a bridge between Asia and Europe. Due to climate change, serious effects are seen in all sectors from energy to agriculture, from the economy to health. Climate change is defined as the most important global health threat of the next century, and the problems it brings are seen as the most important pressure factor for the life opportunities of future generations. Food and fresh water availability, rising sea levels, abnormal weather events, migration, and diseases are thought to affect human health. A multidisciplinary approach is required to adapt to climate change's health effects and reduce its negative health effects. In addition, it is predicted that diseases that are about to disappear will re-emerge and become threats. It is thought that as a result of the contamination of food and water resources with the changing ecosystem, some infections will increase and society will face them. Nurses are both affected by climate change and its effects on public health. Nurses who remain in this situation have a great role in providing effective awareness for raising public awareness. In recent years, oncology clinics have not been affected by fire, earthquakes, and pandemics in our country. In this respect, it can be stated that the health service in Turkish oncology clinics is carried out uninterruptedly and by experts in the field. We learned during the pandemic that the whole world is unprepared for the future effects of climate change. In this direction, nurses should thinkPublication Metadata only A case of pathologic complete response after neoadjuvant triplet chemotherapy for locally advanced colon cancer with mismatch repair enzyme proficiency(Via Medica, 2023) Kocak, Mehmet Zahid; Cakir, Murat; Kerimoglu, Ulku; Araz, Murat; Eryilmaz, Melek Karakurt; Artac, Mehmet; Yumuk, Perran Fulden; School of MedicinePatients with potentially resectable colon cancer and expected to have negative margins should undergo resection rather than neoadjuvant chemotherapy. Recent studies have suggested that neoadjuvant immunotherapy may be an option for tumors with mismatch repair enzyme deficiency (dMMR), but standard treatment for locally advanced colon cancer with mismatch repair enzyme proficiency (pMMR) is still unclear. A 37-year-old male patient was diagnosed with clinical stage IIIC (T4b N1a M0) transverse colon cancer. Mismatch repair proteins were proficient. After 3 cycles of oxaliplatin (85 mg/m(2), day 1), irinotecan (150 mg/m2, IV, day 1), leucovorin (200 mg/m(2), IV, day 1), and 5-fluorouracil (3000 mg/m(2), 46 hours of continuous infusion initiating from day 1), there was a remarkable reduction in the tumoral mass on the abdominal computed tomography. A right hemicolectomy was performed. A pathologic complete response was obtained. Although there is no consensus on which patients are suitable for neoadjuvant therapy in pMMR locally advanced colon cancer, triplet chemotherapy may be a reasonable option in selected patients.Publication Metadata only Systemic inflammation score for predicting radiation-induced trismus and osteoradionecrosis of the jaw rates in locally advanced nasopharyngeal carcinoma patients(Akad Doktorlar Yayınevi, 2023) Somay, Efsun; Besen, Ali Ayberk; Mertsoylu, Huseyin; Topkan, Erkan; Sezen, Duygu; Selek, Uğur; School of MedicineWe sought to determine the predictive value of the systemic inflammation score (SIS) for radiation-induced trismus (RIT) and osteora-dionecrosis of the jaw (ORNJ) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradio-therapy (C-CRT). LA-NPC patients (n= 188) who underwent C-CRT and pre-and post-C-CRT oral examinations from August 2010 to January 2022 were included. The three-tiered SIS groups were created using the serum albumin and lymphocyte-to-monocyte ratio (LMR) measures obtained on the first day of C-CRT: SIS-0: Albumin >= 40 g/dL and LMR >= 4.44); SIS-1: Albumin < 40 g/dL and LMR < 4.44 or albumin >= 0 g/dL and LMR >= 4.44; and SIS-2: Albumin < 40 g/dL and LMR <4.44. The primary objective was to ascertain whether there were irrefutable associations between pretreatment SIS groups and the respective post-C-CRT RIT and ORNJ rates. RIT and ORNJ were diagnosed in 33 (17.6%) and 21 (11.1%) patients, respectively. There were 12 (32.4%), 13 (12.7%), and 18 (45.0%) cases diagnosed with RIT in the respective SIS-0, SIS-1, and SIS-2 groups (p< 0.001). Similarly, there were 1 (2.7%), 11 (9.9%), and 9 (22.5%) cases with ORNJ diagnoses in the corresponding SIS groups (p< 0.001). The multivariate analysis's findings revealed that the SIS grouping was an independent predictor of RIT (p< 0.001) and ORNJ incidence rates (p< 0.001). Our study's findings indicate that the novel pretreatment SIS grouping is a dependable biomarker-based system, which can accurately predict the rates of RIT and ORNJ in LA-NPC patients who receive definitive C-CRT.Publication Metadata only Design considerations for clinical trials of radiotherapy combined with immunotherapy(Kare Publ, 2023) Welsh, James; Sezen, Duygu; School of MedicineThe discovery of synergistic effects between radiation and immunotherapy in pre-clinical studies has encouraged researchers to conduct clinical trials testing the effects of combined therapy in patients. The first step in conducting any clinical trial is to define the hypothesis and core objectives. The challenge while developing trials analyzing combinations of immunotherapy and radiation therapy (RT) is to select an appropriate hypothesis that can be tested in the future research, as well as raising new questions for investigation. Here, we review some of the concerns and challenges for designing clinical trials of RT combined with immunotherapy.Publication Metadata only Comment on: intensity modulated radiotherapy in head and neck cancer: initial experience of the first treated cases from North-East India(Springer India, 2023) Topkan, Erkan; Somay, Efsun; Selek, Uğur; School of MedicineN/A